[go: up one dir, main page]

JP4571800B2 - 新規化合物 - Google Patents

新規化合物 Download PDF

Info

Publication number
JP4571800B2
JP4571800B2 JP2003515517A JP2003515517A JP4571800B2 JP 4571800 B2 JP4571800 B2 JP 4571800B2 JP 2003515517 A JP2003515517 A JP 2003515517A JP 2003515517 A JP2003515517 A JP 2003515517A JP 4571800 B2 JP4571800 B2 JP 4571800B2
Authority
JP
Japan
Prior art keywords
amino
aminocarbonyl
nmr
dmso
thiophenecarboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003515517A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005503372A (ja
JP2005503372A5 (no
Inventor
アラン・フォール
クレイグ・ジョンストーン
アンドリュー・モーリー
ジェフリー・フィリップ・ポイザー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2005503372A publication Critical patent/JP2005503372A/ja
Publication of JP2005503372A5 publication Critical patent/JP2005503372A5/ja
Application granted granted Critical
Publication of JP4571800B2 publication Critical patent/JP4571800B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2003515517A 2001-07-25 2002-07-19 新規化合物 Expired - Fee Related JP4571800B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0102616A SE0102616D0 (sv) 2001-07-25 2001-07-25 Novel compounds
PCT/SE2002/001403 WO2003010158A1 (en) 2001-07-25 2002-07-19 Novel compounds

Publications (3)

Publication Number Publication Date
JP2005503372A JP2005503372A (ja) 2005-02-03
JP2005503372A5 JP2005503372A5 (no) 2009-11-05
JP4571800B2 true JP4571800B2 (ja) 2010-10-27

Family

ID=20284944

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003515517A Expired - Fee Related JP4571800B2 (ja) 2001-07-25 2002-07-19 新規化合物

Country Status (22)

Country Link
US (3) US7125896B2 (no)
EP (1) EP1421074B1 (no)
JP (1) JP4571800B2 (no)
KR (1) KR100931172B1 (no)
CN (1) CN1263751C (no)
AT (1) ATE482944T1 (no)
AU (1) AU2002355245B2 (no)
BR (1) BR0211473A (no)
CA (1) CA2454703C (no)
CY (1) CY1111543T1 (no)
DE (1) DE60237828D1 (no)
DK (1) DK1421074T3 (no)
ES (1) ES2351436T3 (no)
HK (1) HK1071129A1 (no)
IL (2) IL160028A0 (no)
MX (1) MXPA04000756A (no)
NO (1) NO326684B1 (no)
NZ (1) NZ530750A (no)
PT (1) PT1421074E (no)
SE (1) SE0102616D0 (no)
WO (1) WO2003010158A1 (no)
ZA (1) ZA200400492B (no)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
SI1401825T1 (sl) * 2001-06-11 2010-01-29 Virochem Pharma Inc Tiofenski derivati kot protivirusna sredstva za flavirusno infekcijo
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
MXPA04004064A (es) * 2001-10-30 2004-09-06 Pharmacia Corp Derivados heteroaromaticos de carboxamida para el tratramiento de la inflamacion.
WO2003104218A1 (en) * 2002-06-06 2003-12-18 Smithkline Beecham Corporation Nf-:b inhibitors
AU2003270701B2 (en) 2002-10-31 2009-11-12 Amgen Inc. Antiinflammation agents
JP2006510676A (ja) * 2002-12-06 2006-03-30 スミスクライン・ビーチャム・コーポレイション ＮＦ−κＢ阻害剤
CN100413861C (zh) 2002-12-10 2008-08-27 维勒凯姆制药股份有限公司 用于治疗或预防黄病毒感染的化合物
SE0300092D0 (sv) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
CA2529790A1 (en) * 2003-06-27 2005-01-27 Banyu Pharmaceutical Co., Ltd. Heteroaryloxy nitrogenous saturated heterocyclic derivative
CA2535652A1 (en) * 2003-08-15 2005-02-24 Astrazeneca Ab Substituted thiophenes and uses thereof
JP2007516270A (ja) * 2003-12-23 2007-06-21 ソマンタ リミテッド 抗ガン性化合物としてのアントラキノン化合物
GB0403744D0 (en) * 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
WO2005105777A1 (en) * 2004-05-05 2005-11-10 Pharmacia & Upjohn Company Llc Substituted thiophene amide compounds for the treatment of inflammation
PE20060373A1 (es) 2004-06-24 2006-04-29 Smithkline Beecham Corp Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
DE602006003661D1 (de) 2005-06-06 2008-12-24 Lilly Co Eli Ampa-rezeptoren-verstärker
DE102005029382B3 (de) * 2005-06-24 2006-12-21 Sanofi-Aventis Deutschland Gmbh Alkoxymethylyl-substituierte Benzoesäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
PE20070173A1 (es) 2005-06-30 2007-03-14 Smithkline Beecham Corp Compuestos de indol carboxamidas como inhibidores de ikk2
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
KR20080052650A (ko) * 2005-09-07 2008-06-11 라보라토리스 세로노 에스.에이. 자궁내막증 치료용 ｉｋｋ 저해제
EP1976828B1 (en) 2005-12-29 2016-12-21 Celtaxsys, Inc. Diamine derivatives as inhibitors of leukotriene a4 hydrolase
WO2008002246A1 (en) * 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
US8106091B2 (en) 2006-11-01 2012-01-31 Chroma Therapeutics Ltd. Inhibitors of IKK-beta serine-threonine protein kinase
MX2009004442A (es) 2006-11-01 2009-05-22 Chroma Therapeutics Ltd Inhibidores de la proteina cinasa de serina-treonina ikk-beta.
NZ576780A (en) * 2006-11-15 2011-12-22 Virochem Pharma Inc Thiophene analogues for the treatment or prevention of flavivirus infections
KR20090109551A (ko) * 2007-01-15 2009-10-20 산텐 세이야꾸 가부시키가이샤 ＩκＢ 키나아제 β 저해 활성을 갖는 신규 인돌 유도체
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
EA201001708A1 (ru) * 2008-04-26 2011-06-30 Хрома Терапьютикс Лтд. Замещённые тиофенкарбоксамиды их применение в качестве ингибиторов ikk-бета серин-треонин протеинкиназ
JP2011525892A (ja) * 2008-06-18 2011-09-29 メルク・シャープ・エンド・ドーム・コーポレイション Ｊａｎｕｓキナーゼの阻害剤
RU2503661C2 (ru) * 2008-07-14 2014-01-10 Сантен Фармасьютикал Ко., Лтд. Новое производное индола, содержащее карбамоильную группу, уреидную группу и замещенную оксигруппу
PL2366699T3 (pl) 2008-10-02 2013-12-31 Asahi Kasei Pharma Corp 8-podstawiona pochodna izochinoliny i jej zastosowanie
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
AU2010236980A1 (en) * 2009-04-16 2011-11-10 Telik, Inc. Substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carbonitriles and substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carboxamides as tubulin polymerization inhibitors
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011030139A1 (en) 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
CN101812007B (zh) * 2010-04-27 2011-11-23 浙江大学 氨基吡咯类化合物及其制备方法
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
WO2012046793A1 (ja) * 2010-10-07 2012-04-12 参天製薬株式会社 ウレイド基とアミノカルボニル基を置換基として有するチオフェン誘導体を有効成分として含有する新規ｊａｋ３阻害剤
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
US9487523B2 (en) 2012-03-14 2016-11-08 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
JP6212534B2 (ja) * 2012-03-14 2017-10-11 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｇｒｐ受容体アンタゴニストの製造方法
ES2864862T3 (es) 2013-03-12 2021-10-14 Celltaxis Llc Métodos de inhibición de la leucotrieno A4 hidrolasa
JP6534650B2 (ja) 2013-03-14 2019-06-26 セルタクシス，インコーポレイテッド ロイコトリエンａ４加水分解酵素の阻害剤
CA2906086A1 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
KR20150127245A (ko) 2013-03-14 2015-11-16 켈탁시스, 인코퍼레이티드 류코트라이엔 a4 가수분해효소의 저해제
EP2821791A1 (en) * 2013-07-04 2015-01-07 Université de Strasbourg 3-aryl propiolonitrile compounds for thiol labeling
BR112016008541B1 (pt) 2013-10-17 2022-11-22 Blueprint Medicines Corporation Composto ou sal farmaceuticamente aceitável, uso do mesmo para tratar mastocistose, tumor do estroma gastrointestinal e leucemia, e composição farmacêutica
JP6344923B2 (ja) * 2014-01-29 2018-06-20 株式会社Uacj 高強度アルミニウム合金及びその製造方法
ES2913282T3 (es) * 2014-05-09 2022-06-01 Shanghai Syncores Tech Inc Ltd Producto intermedio de vortioxetina y procedimiento de síntesis del mismo
US11040979B2 (en) 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
WO2019232306A1 (en) 2018-05-31 2019-12-05 Celtaxsys, Inc. Method of reducing pulmonary exacerbations in respiratory disease patients
EP3953357B1 (en) 2019-04-12 2024-04-17 Blueprint Medicines Corporation Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases
CA3136707A1 (en) 2019-04-12 2020-10-15 Blueprint Medicines Corporation Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468012A (en) * 1973-08-09 1977-03-23 Beecham Group Ltd 2-amino-3-carboxy-thiophene derivatives
DE3529247A1 (de) 1985-05-17 1986-11-20 Bayer Ag, 5090 Leverkusen Verwendung von thienylharnstoffen und -isoharnstoffen als leistungsfoerdernde mittel bei tieren, neue thienylharnstoffe und -isoharnstoffe und ihre herstellung
GB2195634B (en) * 1986-10-01 1990-08-15 Roussel Lab Ltd Thiophene derivatives
JPH02193990A (ja) * 1989-01-20 1990-07-31 Taisho Pharmaceut Co Ltd チオフェンカルボン酸誘導体
US5258357A (en) * 1989-10-07 1993-11-02 Basf Aktiengesellschaft Carboxamides, their preparation and their use as herbicides
US5378703A (en) * 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
US5571810A (en) * 1990-06-11 1996-11-05 Fujisawa Pharmaceutical Co., Ltd. Thiophene derivatives
US5514801A (en) * 1992-12-29 1996-05-07 Monsanto Company Cyclic sulfone containing retroviral protease inhibitors
JPH09194476A (ja) * 1996-01-12 1997-07-29 Taisho Pharmaceut Co Ltd チオフェンアルカン酸誘導体
AU3044197A (en) 1996-07-11 1998-02-09 Pfizer Inc. Pyridylpyrrole compounds useful as interleukin- and tnf antagonists
PT853083E (pt) 1997-01-06 2001-12-28 Pfizer Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica
US6809088B2 (en) * 1997-03-24 2004-10-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6037340A (en) 1997-05-28 2000-03-14 Cadus Pharmaceutical Corporation Synthesis and use of thiophene- and pyrrole-based heteroaromatic compounds
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
US20020002199A1 (en) * 1998-03-12 2002-01-03 Lone Jeppesen Modulators of protein tyrosine phosphatases (ptpases)
AU2713799A (en) 1998-03-12 1999-09-27 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
DK1095016T3 (da) * 1998-07-08 2006-03-13 Sanofi Aventis Deutschland Svovlsubstituerede sulfonylaminocarboxylsyre-N-arylamider, deres fremstilling, deres anvendelse og farmaceutiske præparater omfattende dem
HN2000000051A (es) * 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
CN100355751C (zh) * 2000-03-29 2007-12-19 西克拉塞尔有限公司 2－取代的4－杂芳基－嘧啶、其组合物及其用途
US6414013B1 (en) * 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
WO2002030353A2 (en) 2000-10-12 2002-04-18 Smithkline Beecham Corporation NF-λB INHIBITORS
US20040024047A1 (en) * 2001-10-12 2004-02-05 Callahan James F. Nf-kb inhibitors
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US6713638B2 (en) * 2001-05-18 2004-03-30 Joel M. Linden 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors
SI1401825T1 (sl) * 2001-06-11 2010-01-29 Virochem Pharma Inc Tiofenski derivati kot protivirusna sredstva za flavirusno infekcijo
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102617D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US7166639B2 (en) * 2001-10-04 2007-01-23 Smithkline Beecham Corporation NF-κB inhibitors
WO2003029241A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2003028731A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
TWI281916B (en) * 2001-10-25 2007-06-01 Lilly Co Eli Antitumor compounds and methods
US6835745B2 (en) * 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents
US7196106B2 (en) * 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
SE0300091D0 (sv) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
US20040242573A1 (en) 2004-12-02
BR0211473A (pt) 2004-10-26
JP2005503372A (ja) 2005-02-03
US20110152234A1 (en) 2011-06-23
US7125896B2 (en) 2006-10-24
ZA200400492B (en) 2005-04-22
DK1421074T3 (da) 2010-12-13
CN1541214A (zh) 2004-10-27
CA2454703A1 (en) 2003-02-06
CA2454703C (en) 2011-01-04
HK1071129A1 (en) 2005-07-08
AU2002355245B2 (en) 2008-05-15
EP1421074B1 (en) 2010-09-29
KR20040018520A (ko) 2004-03-03
WO2003010158A1 (en) 2003-02-06
US20070015819A1 (en) 2007-01-18
US7956084B2 (en) 2011-06-07
CN1263751C (zh) 2006-07-12
NO326684B1 (no) 2009-01-26
PT1421074E (pt) 2010-11-29
KR100931172B1 (ko) 2009-12-11
ATE482944T1 (de) 2010-10-15
MXPA04000756A (es) 2004-04-20
SE0102616D0 (sv) 2001-07-25
IL160028A (en) 2012-01-31
NO20040313L (no) 2004-03-25
NZ530750A (en) 2005-08-26
CY1111543T1 (el) 2015-08-05
ES2351436T3 (es) 2011-02-04
DE60237828D1 (de) 2010-11-11
IL160028A0 (en) 2004-06-20
EP1421074A1 (en) 2004-05-26

Similar Documents

Publication Publication Date Title
JP4571800B2 (ja) 新規化合物
AU2002355245A1 (en) Novel compounds
DE60218048T2 (de) Thiophenverbindungen als arzneimittel
US7358376B2 (en) Substituted Thiophene compounds
US20070219266A1 (en) N-Acylated-3-(Benzoyl)-Pyrrolidines as 11-Beta-HSD1 Inhibitors Useful for the Treatment of Metabolic Disorders
KR100966273B1 (ko) 아미노알킬-치환된 아제티딘, 피롤리딘, 피페리딘 및아제판의 아미드
EP1910307A1 (en) Pyrazole based lxr modulators
JP4879739B2 (ja) チエノピラゾール
TWI670267B (zh) 新穎ｐｄｅ４抑制劑
US7820675B2 (en) Benzofuran compounds
EP1725232B1 (en) (indol-3-yl)-heterocycle derivatives as agonists of the cannabinoid cb1 receptor
MXPA04006856A (es) Agentes virales de 4-oxo-4,7-dihidrofuro[2,3-b]piridin-5carboxamida.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050607

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090317

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090616

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090717

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090817

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090824

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20090909

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100526

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100707

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100803

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100813

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130820

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees